Alkeon Capital Management LLC Boosts Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC

Alkeon Capital Management LLC grew its position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 12.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,504,096 shares of the company’s stock after acquiring an additional 500,000 shares during the quarter. Alkeon Capital Management LLC owned about 4.64% of Oric Pharmaceuticals worth $45,717,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Oric Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 3,215,887 shares of the company’s stock valued at $17,945,000 after purchasing an additional 12,098 shares during the last quarter. Vivo Capital LLC raised its position in shares of Oric Pharmaceuticals by 50.3% in the second quarter. Vivo Capital LLC now owns 3,126,604 shares of the company’s stock valued at $31,735,000 after buying an additional 1,046,154 shares during the last quarter. MPM Bioimpact LLC raised its position in shares of Oric Pharmaceuticals by 23.6% in the second quarter. MPM Bioimpact LLC now owns 1,729,378 shares of the company’s stock valued at $17,553,000 after buying an additional 329,864 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Oric Pharmaceuticals by 3,646.1% in the second quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock worth $13,555,000 after buying an additional 1,299,799 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in Oric Pharmaceuticals by 1.9% during the second quarter. Franklin Resources Inc. now owns 1,042,558 shares of the company’s stock worth $10,582,000 after acquiring an additional 19,768 shares during the last quarter. 95.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, CEO Jacob Chacko sold 125,000 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $10.80, for a total transaction of $1,350,000.00. Following the transaction, the chief executive officer directly owned 656,419 shares in the company, valued at $7,089,325.20. This represents a 16.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Dominic Piscitelli sold 11,000 shares of the firm’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $14.52, for a total value of $159,720.00. Following the transaction, the chief financial officer owned 48,317 shares of the company’s stock, valued at approximately $701,562.84. This represents a 18.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 261,000 shares of company stock worth $3,024,703. Company insiders own 6.82% of the company’s stock.

Oric Pharmaceuticals Stock Down 3.2%

Shares of Oric Pharmaceuticals stock opened at $9.38 on Friday. The firm has a market cap of $913.51 million, a PE ratio of -5.42 and a beta of 1.32. Oric Pharmaceuticals, Inc. has a 52 week low of $3.90 and a 52 week high of $14.93. The business’s fifty day simple moving average is $12.27 and its 200-day simple moving average is $10.91.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.08. As a group, equities analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on the stock. Wells Fargo & Company increased their price objective on shares of Oric Pharmaceuticals from $19.00 to $25.00 and gave the company an “overweight” rating in a report on Monday. Wall Street Zen lowered Oric Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 23rd. Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of Oric Pharmaceuticals in a research report on Monday, December 8th. Oppenheimer boosted their price objective on Oric Pharmaceuticals from $12.00 to $15.00 and gave the stock an “outperform” rating in a research note on Friday, November 14th. Finally, Evercore ISI assumed coverage on Oric Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $25.00 target price for the company. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.